This site is intended for healthcare professionals

Molecular Targeted Therapy News 1/2015 Czech edition

Efficacy and tolerability of axitinib in metastatic renal cell carcinoma (mRCC): Comparison of Czech clinical registry and AXIS trial data

Bohuslav Melichar,1 Alexandr Poprach,2 Katerina Kubackova,3 Ondrej Fiala,4 Hana Studentova,1 Petra Holeckova,5 Radek Lakomy,2 Karel Hejduk,6 Rostislav Vyzula,2 Tomas Buchler7

1 Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
2 Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Zluty kopec 7, Brno, Czech Republic
3 Department of Oncology, University Hospital Motol, Prague, Czech Republic
4 Department of Oncology and Radiotherapy, Medical School and Teaching Hospital Pilsen, Charles University, Prague, Czech Republic
5 Institute of Radiation Oncology, Charles University First Medical School and Hospital Bulovka, Prague, Czech Republic
6 Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
7 Department of Oncology and First Faculty of Medicine, Charles University and Thomayer Hospital, Videnska 800, Prague 140 59, Czech Republic

Abstract Background: The present retrospective analysis was conducted to evaluate the efficacy of axitinib, a potent and specific inhibitor of vascular endothelial growth factor receptors 1, 2 and 3, as second-line therapy for mRCC in real-world clinical practice. The database of the Czech Clinical Registry of Renal Cell Cancer Patients was used, to which healthcare...

Zpět

Diabetology News č. 1/2023 Czech edition

03 | 02 | 2023

Česká diabetologie č. 1/2023

03 | 02 | 2023

Event Report – ASH®

03 | 02 | 2023




Partneři projektu